10 August 2021
Latham & Watkins Advises the Underwriters in Eliem Therapeutics’ Initial Public Offering
Advising firms
Deal team
13 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Brian Cuneo Lead | Latham & Watkins LLP | Partner | capital markets | Bay Area |
| Phillip Stoup Lead | Latham & Watkins LLP | Partner | capital markets | Bay Area |
| Nimrah Khan | Latham & Watkins LLP | Associate | capital markets | Bay Area |
| Kevin Cergol | Latham & Watkins LLP | Associate | capital markets | Bay Area |
| Chris Hazuka | Latham & Watkins LLP | Partner | intellectual property | Bay Area |
| Stephanie Blij | Latham & Watkins LLP | Associate | intellectual property | Bay Area |
| Elizabeth Richards | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Counsel | regulatory | Bay Area |
| Meryl Bartlett | Latham & Watkins LLP | Associate | regulatory | Washington, D.C. |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Jessica Chen | Latham & Watkins LLP | Associate | tax | Bay Area |
| Jay Metz | Latham & Watkins LLP | Partner | benefit and compensation | Bay Area |
| Samantha Voutyras | Latham & Watkins LLP | Associate | benefit and compensation | Chicago |
Stated terms
- Stated value
- USD 80m (US$80 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Eliem Therapeutics, Inc. (Issuer)